Organogenesis Holdings Inc reports results for the quarter ended March 31 - Earnings Summary
08/05/2025 22:43
Organogenesis Holdings Inc ORGO.OQ reported a quarterly adjusted loss of 10 cents per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -2 cents. The mean expectation of four analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -9 cents to -3 cents per share. Revenue fell 21.2% to $86.69 million from a year ago; analysts expected $90.77 million. Organogenesis Holdings Inc's reported EPS for the quarter was a loss of 17 cents. The company reported a quarterly loss of $21.59 million. Organogenesis Holdings Inc shares had risen by 19.9% this quarter and gained 61.9% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 1,233.4% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Organogenesis Holdings Inc is $6.00 This summary was machine generated from LSEG data May 8 at 09:43 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.06 | -0.10 | Missed |
| Dec. 31 2024 | -0.01 | 0.06 | Beat |
| Sep. 30 2024 | -0.01 | 0.09 | Beat |
| Jun. 30 2024 | 0.00 | 0.04 | Beat |
Recent news on Organogenesis Holdings
See all newsBrief: Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Organogenesis Q2 Net Product Revenue USD 42.8 Million
Organogenesis Holdings Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers